AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05878600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical spine strengthening
Description: sole effect of cervical spine strengthening will be analyzed
Study NCT06344065 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed)
Description: Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for experimental vaccine is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.
Study NCT06344065 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed)
Description: Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for active control vaccine 1 is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.
Study NCT06344065 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed) and Haemophilus influenzae type b conjugate vaccine
Description: Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for active control vaccine 2 is through intramuscular injection of 0.5ml into the anterolateral side of the thigh or the upper arm.
Study NCT04996992 — intervention group
Intervention type: PROCEDURE
Intervention: MR-guided focused ultrasound
Description: MR-guided focused ultrasound pallidothalamic tractotomy is a minimally invasive and effective procedure for thetreatment of Parkinson's disease(PD) patients.
Study NCT06533111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epic Health Record semi-structured handoff cognitive aid
Description: Epic Health Record cognitive aid will be used for intraoperative anesthesia handoff
Study NCT06533111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Epic Health Record cognitive aid will not be used for intraoperative anesthesia handoff
Study NCT05647512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-305
Description: Administered intravenously
Study NCT04556227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simultaneous Cycle/Cognitive Training
Description: Two weeks after discharge from the hospital the intervention group will complete recumbent cycle for 1 hour, 2x/wk. for 12 weeks (24 sessions). 10-minute cycle warm-up, 40-minute simultaneous cycling and cognitive training, 10-minute cool down. Cycling based on provider prescription and progression of physical recovery. Cognitive training program from Posit Science, Brain HQ (TM) progressive level of difficulty. Total duration of 60 minutes.
Study NCT06470373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBS-001 Solution for intravitreal injection
Description: Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye
Study NCT05647512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Administered orally
Study NCT06192771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESSI-SURG
Description: Patients will receive 3 face-to-face sessions with a speech-language pathologist (SLP), each with a specific goal, namely: pre-surgical educational, a post-operative day 3 therapy, and post-operative day 7 therapy. Following discharge from hospital, participants will be seen by an SLP for 4 weekly sessions, offered via telehealth or face-to-face depending on the patient's clinic schedule and/or availability.
Study NCT06192771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care
Description: Participants will receive the current standard of care, which includes a referral to SLP in response to suspicion of a swallowing problem from either assessment by the medical team and/or patient report.
Study NCT05304559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Ketamine
Description: S-Ketamine0.1mg/kg was injected intravenously during anesthesia induction and S-Ketamine0.1mg/ (kg.h) was injected intravenously during anesthesia maintenance.S-Ketamine was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
Study NCT05304559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous iliac fascia space block
Description: After admission, the iliac fascia space block and catheterization were performed under the guidance of ultrasound, and the analgesia was continued until two days after operation.
Study NCT05304559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline0.1ml/kg was injected intravenously during anesthesia induction and Normal saline0.1ml/ (kg.h) was injected intravenously during anesthesia maintenance.Normal saline was put into the analgesia pump as an adjuvant for continuous analgesia until 2 days after operation.
Study NCT05167344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Relationships Program-Enhanced
Description: The Healthy Relationships Program-Enhanced (HRP-E) is a small group mental health promotion and healthy relationship program designed for vulnerable, at-risk youth. It is a trauma-informed, 16-session manualized program.
Study NCT05596669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: to examine the pain-relieving effects of ketamine vs ketamine magnesium infusion, as well as their influence on postoperative morphine consumption following nephrectomy; the secondary goal is to assess hemodynamic effects and pain severity
Study NCT05434312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGRX-678
Description: Participants are given TGRX-678 tablets orally at one of the dose levels as pre-determined for the dose escalation sequence.
Study NCT04796610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mopati
Description: The intervention will provide training to health care providers on how to guide unsuppressed HIV patients in the selection of treatment partners. The Mopati program will provide education to patients and their treatment partners about HIV treatment and how treatment partners can support patients in treatment adherence.
Study NCT06335771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary consultation weight loss intervention
Description: Participants will meet with a member of the study team biweekly for about 6 months.
Study NCT05574348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Protocol in 2 Sessions (PO2S)
Description: PO2S works on the principle that there is a concordance between the author's Preferential Torsion Pattern (PTP) and the rotatory direction of osteopathic dysfunctions.~The PO2S consists of two sessions of 30 minutes each, one week apart. A 13-item clinical examination is performed at the first session. It focuses on caused pain tests, and classifies patients in left or right PTP. During the first session 14 normalizations of joint, muscular, ligament and visceral dysfunctions are performed systematically. During the second session 10 normalizations of joint, muscular, ligament and visceral dysfunctions are performed .~PO2S is an innovative osteopathic protocol for back pain.
Study NCT06377839 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Advanced platelet-rich fibrin in the ekstraction socket
Description: Advanced platelet-rich fibrin is a centrifuged fibrin matrix composed of concentrated growth factors, platelet cytokines, and blood cells, which possesses the ability to stimulate wound healing and tissue regeneration. Advanced platelet-rich fibrin is manufacturing from a blood sample.
Study NCT06377839 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Advanced platelet-rich fibrin in the ekstraction socket
Description: Advanced platelet-rich fibrin is a centrifuged fibrin matrix composed of concentrated growth factors, platelet cytokines, and blood cells, which possesses the ability to stimulate wound healing and tissue regeneration. Advanced platelet-rich fibrin is manufacturing from a blood sample.
Study NCT05856292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teach Back
Description: Standard cancer pain educational intervention enhanced with teach-back method
Study NCT05856292 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard cancer pain educational intervention without enhancement
Study NCT04886141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: To determine if virtual reality headsets can reduce a patients pain level instead of using the standard Nitrous. This may provide a alternate to patients who cannot receive nitrous if pain or anxiety can be reduced effectively.
Study NCT04689737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine
Description: Participants will be told to take one tablet of doravirine (Pifeltro, MDS) once daily, with or without food, approximately at the day time that they usually finish the hemodialysis sessions. The rest of their antiretroviral regimen and concomitant medications will remain unchanged
Study NCT05061446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Etrasimod tablet by mouth, once daily for 12 weeks
Study NCT05061446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etrasimod matching placebo tablet by mouth, once daily up to 12 weeks
Study NCT04875806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC762
Description: NC762 is an experimental antibody drug that may make the immune response more active against cancer
Study NCT06053658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Given by PO
Study NCT06053658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV (vein)
Study NCT06470373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eylea® Solution for intravitreal injection
Description: Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye
Study NCT05224947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula
Description: Two infant formulas differing in composition
Study NCT06406205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin（QL1074）
Description: QL1074 23.7 mg BlD will be administered as a fixed dose without the use of therapeutic drugmonitoring. The protocol contains provisions for management of dose based on safety concerns, in particular, BP and renal function，can be managed by dose reduction and temporary of QL1074 to interruption.
Study NCT06406205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo softgel capsules, identical to 7.9 mg QL1074, will be provided. The administration plan and dosage management regulations are the same as QL1074.
Study NCT04801446 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soterix Medical 1X1 tDCS stimulator (active C-tDCS)
Description: Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.
Study NCT04801446 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Soterix Medical 1X1 tDCS stimulator (sham stimulation)
Description: Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the headgear and electrodes in place, and the switch for sham stimulation will be on, i.e. no prolonged electrical stimulation will be delivered.
Study NCT06430372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bev-ICG
Description: Probe targeting VEGF-A that is topically administrated during the endoscopy
Study NCT06430372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIR-II fluorescence endoscopy platform
Description: An endoscopic detection device which can detect and visualize NIR-II fluorescent signal during the endoscopy
Study NCT05474144 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SmartProbio C
Description: Probiotic supplement consisting of 19 strains (Lactobacillus acidophilus NCFM, Bifidobacterium lactis, subsp. Infantis Bi-07, Lactobacillus rhamnosus LR22, Lactobacillus acidophilus LA14, Lactobacillus rhamnosus LGG, Bifidobacterium lactis HN019, Bifidobacterium lactis Bl-04, Lactobacillus acidophilus LA 11 ONLLY, Lactobacillus rhamnosus HN001, Lactobacillus plantarum LP ONLLY, Lactobacillus casei LC18, Bifidobacterium breve BB8, Lactobacillus reuteri LE16, Bifidobacterium lactis BI516, Streptococcus thermophilus ST6, Bifidobacterium animalis BA77, Bifidobacterium bifidum BB47, Bifidobacterium longum BL88 ONLLY, Bifidobacterium infantis BI211) in different ratios. Probiotic mixture enclosed in HPMC (hydroxypropylmethylcelulose) capsule, 25 billion CFU (colony-forming units) in each capsule. As a filling agent mix of inulin and maltodextrin was used. Dosage twice a day.
Study NCT05474144 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo. HPMC (hydroxypropylmethylcelulose) capsule filled with maltodextrin. Dosage twice a day.
Study NCT05486949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4205 and carbamazepine
Description: All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with carbamazepine after the wash-out period.
Study NCT05486949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4205 and itraconazole
Description: All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with itraconazole after the wash-out period.
Study NCT05942456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA: enzyme-linked immunosorbent assay
Description: enzyme-linked immunosorbent assay
Study NCT05566730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CT-MICART App
Description: App designed with the goal of treating CUD in African American adults
Study NCT05566730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: App designed with the goal of treating CUD in African American adults, with participants just tracking their use of cannabis and not receiving treatment videos
Study NCT06456021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Relational Playbook
Description: The Relational Playbook consists of 5 chapters and hosts research-based resources and 50 evidence-based interventions presented in short, digestible content to create supportive learning environments. Implementation is guided by 4-steps: Step 1) Assess the current state: CCL managers assesses the current state of their learning environment through a 13-item Learning Environment Assessment Tool. Results are automatically scored and grouped by Playbook chapters. A summary report is immediately available with guidance on how to interpret results. Step 2) Select areas for improvement: CCL managers determine which Playbook chapters and interventions to adopt. Step 3) Implement/adapt interventions: Over the 6-month intervention period, CCL managers are required to implement interventions from 2-3 Playbook chapters. They may adapt the delivery method/implement additional interventions. Step 4) Evaluate the impact: CCL managers develop feedback loops to monitor intervention performance.
Study NCT06456021 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Relational Playbook
Description: The Relational Playbook consists of 5 chapters and hosts research-based resources and 50 evidence-based interventions presented in short, digestible content to create supportive learning environments. Implementation is guided by 4-steps: Step 1) Assess the current state: CCL managers assesses the current state of their learning environment through a 13-item Learning Environment Assessment Tool. Results are automatically scored and grouped by Playbook chapters. A summary report is immediately available with guidance on how to interpret results. Step 2) Select areas for improvement: CCL managers determine which Playbook chapters and interventions to adopt. Step 3) Implement/adapt interventions: Over the 6-month intervention period, CCL managers are required to implement interventions from 2-3 Playbook chapters. They may adapt the delivery method/implement additional interventions. Step 4) Evaluate the impact: CCL managers develop feedback loops to monitor intervention performance.
Study NCT06456021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leadership Coaching
Description: Leadership coaching is a novel implementation strategy that enables proactive, knowledgeable, and supportive leadership behaviors. Although coaching has been embraced in the VA, through Whole Health and the VA Leadership Coaching Program, no studies have examined the impact on innovation implementation with clinical managers.
Study NCT05552391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Group bupivacaine(Control) (B) received 0.5 ml/kg bupivacaine 0.25% diluted with isotonic saline (total volume15 ml).
Study NCT05552391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Group bupivacaine(Control) (B) received 0.5 ml/kg bupivacaine 0.25% diluted with isotonic saline (total volume15 ml).
Study NCT05283096 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire about beliefs on food and diet in rheumatic diseases, and if a diet was tried what effect it had on health and rheumatism
Study NCT04524962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Descartes 30
Description: Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.
Study NCT06040346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meplazumab for Injection
Description: Meplazumab, an erythrocytic stage-macromolecular antibody drug, has the potential to control clinical occurrence of falciparum malaria. Meplazumab is a humanized anti-CD147 immunoglobulin G subclass 2 (IgG2) monoclonal antibody with strong affinity to CD147. CD147 is expressed on erythrocyte lineage cells throughout erythroid development, including mature erythrocytes and is the target for Plasmodium merozoites to allow reorientation and subsequent invasion of the erythrocytes.
Study NCT04387162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prism Adaptation Treatment
Description: Spatial retraining treatment
Study NCT05004922 — intervention group
Intervention type: OTHER
Intervention: Embryo transfer into upper cavity
Description: Transfer of embryos in upper cavity
Study NCT05004922 — intervention group
Intervention type: OTHER
Intervention: Embryo transfer into midcavity
Description: Transfer of embryos in mid cavity
Study NCT06289413 — intervention group
Intervention type: OTHER
Intervention: Development of AD/OI after BS
Description: OI is a type of AD that results in chronic supine-to-standing hypotension and disabling dizziness, lightheadedness, and even syncope. Whether arising from malabsorption, vagus nerve damage, or splanchnic vasodilation, the pathophysiology of OI in bariatric surgery is not clear and requires more investigation.~Treatment of OI usually consists of dietary and lifestyle changes, which may include compression stockings and abdominal binders. Medical options include peripheral vasoconstrictors and mineralocorticoids; some patients may be referred to Cardiology for further testing. Management is difficult and endurance and tilt training, inflatable abdominal bands, and beta-blockers have been proposed. One recent study demonstrated the treatment of refractory OI with Droxidopa. Yet, the success of treatment is individualized and necessitates more novel approaches.
Study NCT05540392 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 10 treatments of acupuncture over the course of 10 weeks
Study NCT05540392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waitlist Control
Description: The waitlist control group will not receive any acupuncture treatments during the 14-week waiting period. Patients in waitlist control group will have the option to receive up to 10 acupuncture treatments after a 14-week waiting period.
Study NCT05540392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients will complete Patient Reported Outcomes (PRO)
Study NCT05597020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: Daridorexant is available as oral film-coated tablets at a strength of 50 mg.
Study NCT05597020 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching daridorexant is provided as identical-looking oral tablets, formulated with the same inactive ingredients (excipients) as the active tablets.
Study NCT04897581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Insomnia, BBTI
Description: BBTI includes sleep hygiene, stimulus control, and sleep restriction, and is administered in three 50-minute sessions over telehealth by psychologic team.
Study NCT04897581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Self-Regulation, PSR
Description: PSR is conducted over telehealth and consists of three 50-minute sessions focused on jaw relaxation exercises, proprioceptive awareness training, and diaphragmatic breathing entrainment.
Study NCT06347354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Subdermal injection of 2,5 mg (1 cc) of ICG